Imatinib is a tyrosine kinase inhibitor (TKI) that specifically targets the breakpoint cluster region(BCR)-Abelson leukemia virus (ABL) fusion protein in chronic myeloid leukemia (CML) and has beenwidely used in the treatment of various cancers [55]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.